PACT Members Make Deloitte fastest-growing list

7 Philadelphia-area companies make Deloitte fastest-growing list
[Featuring PACT Members, Phenom People, Inc., Sidecar Interactive, Inc., Spark Therapeutics, Inc.]

Written by Kennedy Rose – Digital Producer, Philadelphia Business Journal

Seven Philadelphia-area companies made the list of Deloitte’s fastest-growing tech companies.

Deloitte’s latestTechnology Fast 500 ranks the fastest-growing technology companies in North America. Deloitte determines growth rate based on percentage fiscal year revenue growth from 2015 to 2018.

Read full article.

Spark Therapeutics completes regulatory filing application for its experimental gene therapy medicine

Written by Linda Loyd, Philadelphia Inquirer 

Drug developer Spark Therapeutics said Thursday that it had completed its biologics license application submission with the Food and Drug Administration for its experimental gene therapy for patients with rare inherited blindness.

If approved by the FDA, Spark’s lead drug candidate, voretigene neparvovec, could be the first U.S. treatment that uses genes as medicine.

The Philadelphia biotech, spun out of Children’s Hospital of Philadelphia, said the FDA will have 60 days to determine whether the application is complete. If the FDA decides the treatment should be given “priority review,” that would set a six-month target review period, said company spokeswoman Monique da Silva. “The review period is still to be determined.”

Click here to read the full article.

Spark reels in second $15M payment from Pfizer

Written by John George of Philadelphia Business Journal

Spark Therapeutics said Wednesday it has received a second $15 million payment from Pfizer, this one for hitting pre-specified safety and efficacy development milestones for an experimental gene therapy treatment of hemophilia B the company’s are co-developing.

The gene therapy candidate, called SPK-9001, has received breakthrough therapy and orphan product designations from the Food and Drug Administration.

Click here to read the full article.